Classification of triple negative breast cancer by epithelial mesenchymal transition and the tumor immune microenvironment.

ABSTRACT: Triple-negative breast cancer (TNBC) accounts for about 15-20% of all breast cancers and differs from other invasive breast cancer types because it grows and spreads rapidly, it has limited treatment options and typically worse prognosis. Since TNBC does not express estrogen or progesterone receptors and little or no human epidermal growth factor receptor (HER2) proteins are present, hormone therapy and drugs targeting HER2 are not helpful, leaving chemotherapy only as the main systemic treatment option. In this context, it would be important to find molecular signatures able to stratify patients into high and low risk groups. This would allow oncologists to suggest the best therapeutic strategy in a personalized way, avoiding unnecessary toxicity and reducing the high costs of treatment.

SUBMITTER: Font-Clos F 

PROVIDER: S-EPMC9187759 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature